Search
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalThis mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.
Nitroxoline
go.drugbank.com/drugs/DB01422ExperimentalIt is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.
Synonyms: 5-NOKLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalIt has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Alferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard
Clesacostat
go.drugbank.com/drugs/DB18956InvestigationalClesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)).
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
Artesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Candoxatrilat
go.drugbank.com/drugs/DB11623ExperimentalA dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy
TAS-102
go.drugbank.com/drugs/DB08937InvestigationalTrifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.